Sunday, February 21, 2010

#6 Refined List of Research Topics

MRSA is a community and hospital acquired disease. It is most prominent in the hospital settings. Usually from individuals with weak immunaity or post-surgery, an infection occurs. Health care providers are sometimes carriers if they don’t wash their hands or disinfectant themselves. Recently, the community acquired MRSA is more prominent. MRSA is becoming a great concern because of its ability to gain resistance to antiobiotics. More specifically, antibiotics that are beta-lactam. These drugs are most commonly used for gram positive bacteria. MRSA is resistant to most of these beta-lactam drugs. Typically, vancomyocin is the last resort drug to treat MRSA. However, there are a few MRSA bacteria that are resistant to vancomyocin. These bacteria are not common but it has raised alarm to health care providers, as they need to make new antibiotics to counteract the increasing antibiotic resistance of MRSA. It is important to discover other antibiotics or even synthetic drugs to keep up with raising antibiotic resistance.
Vaccinia is a virus that was used for small pox vaccination because the two viruses look similar. The virus has the ability to alter protein production on the cell membrane surface. A long protein flagella like knocks off any virus trying to invade the cell. Vaccinia is not harmful to humans and does not cause disease. Viruses that can invade a cell and bump out other viruses. Scientists have been trying to utilize its mechanisms to try to cure other viruses. There are other viruses with a similar invasion method such as herpes. If Scientists can understand this concept better and iutilize it, it can be used to cure or surpress the disease.
Artificial retina is important for people who have lost sight. These synthetic retinas should beable to reflect light and rely it to the brain. Eyesight requires ganglion and bipolar neurons to fire an actionpotential to the brain for intergration. I don’t know a lot about artificial retina production.

0 comments:

Post a Comment